GARY WARSTADT: Open Payments
NPI 1639155013 · RANDOLPH, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$713 in 35 payments from 11 companies in 2025. Trend: 2023 $902 · 2024 $773 · 2025 $713
Food & beverage: $713
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $147 |
| ABBVIE INC. | 7 | $142 |
| Neurocrine BioSciences, Inc. | 4 | $85 |
| E.R. Squibb & Sons, L.L.C. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $26 |
| Alkermes, Inc. | 1 | $24 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, COBENFY, FANAPT, REXULTI, AUSTEDO XR, Jornay PM.
Industry payments across MA — which companies pay providers there.
